Very significant information @kpax.
If the top line results from the Fight MND trial are as good as we all expect, then application to participate in the Healey ALS Platform appears to be a logical next step for PAA.
Had a look at their website:
https://www.massgeneral.org/neurology/als/research/about-platform-trial
Savings on costs, time and recruitment tick all the boxes.
Add to that the strong potential of Orphan Drug Designation and we are off to the races !
Trial Centre Monepantel Pharmaust, page-5
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $99.76M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 20.5¢ | 20.0¢ | $86.39K | 425.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 245685 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 204582 | 4 |
View Market Depth
| Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
| PAA (ASX) Chart |